Three annexin A2 pseudogenes, including ANXA2P1, ANXA2P2, and ANXA2P3, are significantly upregulated, along with their parent gene annexin A2 (ANXA2), which is correlated with poor survival outcome of glioma patients (Li et al., 2017b). This evidence concerns the gene ANXA2 and central nervous system cancer.